Welcome to our dedicated page for INCYTE SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
INCYTE CORP (INCY) announced an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) aimed at improving patient access to its medicines while supporting continued U.S. biopharmaceutical innovation. Under this agreement, state Medicaid programs will be able to access Incyte’s products Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations.
Incyte also expects that, under this arrangement, it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. The company stated that it does not expect this agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook.
INCYTE CORP (INCY) reported an insider equity transaction by Ramitpal K. Basi, EVP, Human Resources. On 2026-08-25, 504 shares of common stock were withheld automatically to satisfy tax withholding obligations upon settlement of previously granted restricted stock units. After this tax-withholding disposition, Basi held 10,993 shares directly, including 9,871 unvested restricted stock unit shares issuable as they vest.
INCYTE CORP (INCY) reported that officer Pablo J. Cagnoni, President, Global Head of R&D, sold 10,801 shares of common stock on 2026-08-19 in an open-market transaction at $125.56 per share, pursuant to a Rule 10b5-1 trading plan. Following this sale, he holds rights to 183,200 shares of common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested.
INCYTE CORPORATION (INCY) officer Pablo Cagnoni filed a notice of proposed sales of company common stock under Rule 144. The filing covers a planned sale of 10,801 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,356,189.76 and shares listed on NASDAQ.
The shares to be sold were acquired upon the vesting of Restricted Stock and Performance Shares during the period from June 1, 2026 through July 15, 2026. Over the prior three months, Cagnoni reported additional sales totaling several small blocks of INCY common stock.
Incyte Corp reported that President, Global Head of R&D Pablo J. Cagnoni sold 10,803 shares of common stock on 2026-08-12 at $120.04 per share in an open-market transaction under a Rule 10b5-1 trading plan. Following this sale, he reported 194,001 shares held directly, including 183,200 shares issuable from unvested restricted and performance stock units.
Pablo Cagnoni filed a notice of proposed sales of 10,803 shares of common stock, with an aggregate market value of $1,296,773.75, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The filing also lists prior sales of 10,640 shares for $1,305,450.33 on August 5, 2026 and 15,888 shares for $1,901,833.32 on July 31, 2026.
Pablo J. Cagnoni, President and Global Head of R&D at Incyte, reported selling 10,640 shares of common stock on August 5, 2026 at $122.69 per share in a code S open-market or private transaction executed under a Rule 10b5-1 trading plan. Following the sale, he reports ownership of 204,804 shares, including 183,200 shares issuable from previously reported, unvested restricted stock units and earned performance stock units.
INCYTE CORP EVP & Chief Scientific Officer Patrick A. Mayes exercised employee stock options covering 2,207 shares at $106.47 on August 5, 2026, then sold 2,207 common shares at $123.99 per share under a Rule 10b5-1 trading plan.
Footnotes state the option award was fully vested and exercisable as of that date and note 59,537 shares of common stock issuable from previously reported restricted stock units that have not vested.
Incyte Corporation affiliate Pablo Cagnoni filed a Form 144 indicating an intention to sell up to 10,640 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a stated aggregate market value of $1,305,450.33 as of the filing.
The filing also notes that these shares were acquired on June 1, 2026 as restricted stock and performance shares from the issuer, and discloses that 15,888 shares of common stock were sold on July 31, 2026 for $1,901,833.32 during the prior three months. Shares outstanding are listed as 202,697,746.
Patrick A. Mayes filed a Form 144 notice to sell up to 2,207 shares of INCY common stock, to be delivered through a stock option exercise and sold for cash through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing also reports prior sales of INCY common shares in the last three months, including 6,055 shares on 08/03/2026 for $729,203.65 and 41,899 shares on 07/31/2026 for $5,005,186.06.